Access to safe and effective medicines is critical for Kenyans, yet many patients still question whether a drug is “original” or generic. Experts emphasize that the real issue is quality, not branding or price, especially as the country faces a growing threat of counterfeit, falsified, and substandard medicines.
According to Dr. Edward Maina Mbugua, Head of Department—Pharmacy at KUTRRH, the correct scientific distinction is between innovator and generic medicines. Innovators are the original patented drugs developed through extensive research, while generics are produced after the patent expires. Both must contain the same active pharmaceutical ingredient, in the same strength, and demonstrate bioequivalence, meaning they work the same in the body. Generics are more affordable because they do not carry research and patent costs, not because they are inferior.
Dr. Mbugua stresses that a quality-assured medicine, whether innovator or generic will effectively treat disease. Generics have greatly expanded access to healthcare in Kenya, but public trust depends on strong regulation and continuous education. Kenya safeguards medicine quality through the Pharmacy and Poisons Board (PPB), which requires rigorous testing before approval, ongoing post-market surveillance, inspections, random sampling, and recalls of non-compliant products. Substandard medicines may contain insufficient or impure ingredients, while counterfeits are illegal imitations that pose serious health risks.
Despite these measures, counterfeit and substandard medicines remain a public health threat, often entering through informal markets and porous borders. Studies show notable levels of substandard, counterfeit, and unregulated medicines, particularly among common drugs such as antibiotics. Globally, the World Health
The organization estimates that one in ten medical products in low- and middle-income countries is fake or substandard, contributing to treatment failure, drug resistance, higher costs, and preventable deaths.
Enforcement efforts have intensified, with illegal outlets shut down, illicit medicines seized, and suspects arrested. New digital traceability systems introduced in 2025 now help track medicines across the supply chain and detect counterfeits in real time, while continental efforts through the African Medicines Agency aim to harmonize regulations. Patients are advised to protect themselves by buying medicines only from licensed pharmacies, checking PPB registration details, avoiding poorly labeled products, and consulting trained pharmacists. As a leading referral and research hospital, KUTRRH remains committed to strict procurement standards, secure supply chains, active pharmacovigilance, and patient education, working closely with national regulators to ensure medicines are safe, effective, and affordable for all.